ClinicalTrials.gg
Status unknownNCT01217034TACTICSUpdated Oct 31, 2017

Transcatheter Arterial Chemoembolization Therapy In Combination With Sorafenib

A Phase 2 interventional study of TACE with sorafenib and TACE alone in Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma and Carcinoma, Hepatocellular, sponsored by Kindai University. Status unknown at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2017-10-31.

Sponsored by Kindai University · Phase 2, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Oct 2017), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
228
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 104 studies testing sorafenib in Carcinoma, Hepatocellular — 5 open to participants now, 7 under way, 1 of them phase 3. Sorafenib · Carcinoma, Hepatocellular.

Planned enrollment
13th of 104
228 · median 44
Started
2010
with 9 others
Phase 2
44 of 104
3 open now
Registered
49th of 104
by date
Lead sponsor
2 of 104
Kindai University

Among the 104 studies testing sorafenib in Carcinoma, Hepatocellular, this one is the 13th largest by planned enrollment, is one of 10 that started in 2010, is one of 44 in phase 2, and was the 49th registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

5 of the 104 studies testing sorafenib in Carcinoma, Hepatocellular are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About sorafenib

Sorafenib: first FDA approval 2005 (NEXAVAR), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 104 studies testing sorafenib in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of the combination therapy with Transcatheter Arterial Chemoembolization (TACE) and sorafenib compared to TACE alone in patients with unresectable hepatocellular carcinoma (HCC) who are not candidates for surgical resection or percutaneous ablation therapy.

Read the detailed description

TACE with sorafenib Group

Sorafenib will be administrated at a dose of 400mg o.d. before the first TACE. After 2days drug rest, TACE will be conducted. Sorafenib will be resumed at a dose of 400mg o.d. from 3 days after TACE(the resumption day can be postponed until 21 days after TACE). When tolerability is confirmed at 1 week after resumption, the dose of sorafenib will be increased to 400mg b.i.d. When tumor increases, TACE will be repeated.

Control group

TACE will be conducted at scheduled day. When tumor increases, TACE will be repeated.

The treatment regimen will be continued until untreatable progression which is defined as follows:

  • Child-Pugh grade C
  • Tumor growth (125 percent from baseline status)
  • Vascular invasion(Vp3,Vp4)
  • Extra hepatic spread which size is more than 10mm
03

Conditions studied

  • Hepatocellular Carcinoma
  • Unresectable Hepatocellular Carcinoma
  • Carcinoma, Hepatocellular
  • Liver Neoplasm

Keywords

  • Transcatheter arterial chemoembolization
  • TACE
  • sorafenib
  • Time to untreatable progression
  • TTUP
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients aged 20 Years or over
  2. Patients who were fully informed of the study beforehand and signed the to participate in the study.
  3. Patients who are expected to live more than 12 weeks.
  4. Patients diagnosed with typical HCC by ,cytology, or diagnostic imaging such as dynamic CT(MRI).Typical HCC is defined by AASLD criteria.
  5. Patients in whom complete resection of the tumor by hepatectomy or complete tumor necrosis by local tumor necrosis therapy(RFA) cannot be expected to succeed.
  6. Patients with tumors which are confirmed to the liver and can be treated by TACE(the maximum diameter equal to or less than 10cm,and the maximum number of nodule equal to or less than 10).
  7. Patients with viable and measurable target lesion.
  8. patients with no or one history of TACE therapy.
  9. patients with an PS(Performance Status) Score of 0 or 1.
  10. patients with class A.
  11. Patients with laboratory values that meet the following criteria:

    1. ≥ 8.5 g/dl
    2. Granulocytes ≥ 1500/mm3
    3. count ≥ 50,000 /mm3
    4. Total serum ≤ 3 mg/dl
    5. and ALT ≤ 6 times
    6. Serum creatinine ≤ 1.5 times upper limits of normal

Exclusion criteria

Exclusion Criteria:

  1. History of malignant tumor, excluding the following cases:

    1. Curatively treated early stage cancer with a low risk of recurrence ,such as carcinoma in situ of the cervix, basal cell carcinoma, superficial bladder tumor, and early gastric cancer.
    2. Malignant tumor that was curatively treated more than 3 years prior to study entry and has not recurred since then
  2. Cardiac disease that meet any of the following criteria:

    1. Class III or higher congestive heart failure
    2. History of symptomatic coronary artery disease or myocardial infarction within 6 months before enrollment
    3. Arrhythmia requiring control by antiarrhythmic drugs such as beta-blockers or digoxin
  3. Serious and active infection, except for and
  4. History of infection
  5. Renal dialysis
  6. Diffuse tumor lesion
  7. Extrahepatic
  8. Vascular invasion
  9. Intracranial tumor
  10. Preexisting or history of hepatic encephalopathy
  11. Clinically uncontrolled ascites or pleural effusion
  12. Clinically severe gastrointestinal bleeding within 4 weeks of the start of treatment
  13. Esophageal and/or gastric varices which has high risk of bleeding
  14. History of thrombosis and/or embolism within 6 months of the start of treatment
  15. History of receiving any of the following therapies:

    1. Systemic chemotherapy for advanced HCC(including sorafenib therapy)
    2. Local therapy, such as radiofrequency ablation, TACE, or hepatic arterial infusion within 3 months of the start of treatment
    3. Current treatment with inducing agents
    4. Invasive surgery within 4 weeks of the start of treatment
    5. History of allogenic transplantation
    6. History of bone marrow transplant or haemopoietic stem cell transplant within 4 weeks of the start of this study
  16. Unable to take oral medications
  17. Gastrointestinal problems that may affect absorption or pharmacokinetics of the study drugs
  18. Use of drugs that may affect absorption or pharmacokinetics of the study drugs
  19. Concurrent disease or disability that may affect evaluation of the effects of the study drugs
  20. Enrollment in another study within 4 weeks of study entry
  21. Female patients who are pregnant, lactating, possibly pregnant, or planning to become pregnant
  22. Risk of allergic reactions to the study drugs
  23. Drug abuse or other physical, psychological , or social problems that may interfere with the participation in the study or evaluation of study results
  24. Any condition that could jeopardize the safety of the patient or their compliance in the study
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
228 participants (estimated)

Study arms

  • Experimental
    TACE with sorafenib

    TACE(on demand) with sorafenib till untreatable progression

    Drug: TACE with sorafenib

  • Active comparator
    TACE alone

    TACE(on demand) till unreatable progression

    Procedure: TACE alone

Interventions

  • DrugTACE with sorafenib

    Drug page: SorafenibStudies of SorafenibSorafenib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Sorafenib will be administrated at a dose of 400mg o.d. before the first TACE. After 2days drug rest, TACE will be conducted. Sorafenib will be resumed at a dose of 400mg o.d. from 3 days after TACE(the resumption day can be postponed until 21 days after TACE). When tolerability is confirmed at 1 week after resumption, the dose of sorafenib will be increased to 400mg b.i.d. When tumor increases, TACE will be repeated.

    Also known as: TACE with Nexavar

  • ProcedureTACE alone

    TACE will be conducted at scheduled day. When tumor increases, TACE will be repeated.

    Also known as: TACE

06

What researchers measure

Primary outcomes

  1. Progression Free Survival

    Patients will be evaluated for these endpoints every 8 weeks

    Time frame: every 8 week

  2. Overall Survival

    The overall survival is defined as time from randomization to death due to any cause, and will be evaluated every 8 weeks in the protocol treatment, and every one year in the follow-up period,respectively.

    Time frame: every 8 week

Secondary outcomes

  1. Time To Progression

    Time to progression is defined as time from randomization to radiological progression and will be evaluated every 8 week.

    Time frame: every 8 weeks

  2. Objective Response Rate

    Objective Response Rate is defined as best response

    Time frame: 4week after TACE

  3. Tumor markers

    Change of tumor markers

    Time frame: every 4 weeks

  4. Safety

    Number of participants with adverse events as a measure of safety and tolerability(According to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0)

    Time frame: every 4 weeks

  5. Time To Untreatable Progression(TTUP)

    Time to untreatable progression is defined as time from randomization to untreatable progression and will be evaluated every 8 week.

    Time frame: every 8 week till untreatable progression, assessed up to 100 months

  6. Time to Child-Pugh C

    Time to Child-Pugh C is defined as time from randomization to Child-Pugh C and will be evaluated every 8 week.

    Time frame: every 8 week till liver deterioration to Child-Pugh C, assessed up to 100 months

  7. Time to intrahepatic tumor progression

    Time to intrahepatic tumor progression is defined as time from randomization to intrahepatic tumor progression and will be evaluated every 8 week.

    Time frame: every 8 week till intrahepatic tumor progression, assessed up to 100 months

  8. Time to vascular invasion

    Time to vascular invasion is defined as time from randomization to vascular invasion and will be evaluated every 8 week.

    Time frame: every 8 week till vascular invasion, assessed up to 100 months

  9. Time to Extrahepatic spread

    Time to extrahepatic spread is defined as time from randomization to extrahepatic spread and will be evaluated every 8 week.

    Time frame: every 8 week till extrahepatic spread, assessed up to 100 months

07

Study locations

1 site
  • Kinki University Hospital
    Osaka-Sayama, Osaka 589-8511, Japan
08

References and documents

Publications

  • Kudo M, Ueshima K, Ikeda M, Torimura T, Tanabe N, Aikata H, Izumi N, Yamasaki T, Nojiri S, Hino K, Tsumura H, Kuzuya T, Isoda N, Moriguchi M, Aino H, Ido A, Kawabe N, Nakao K, Wada Y, Ogasawara S, Yoshimura K, Okusaka T, Furuse J, Kokudo N, Okita K, Johnson PJ, Arai Y. Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma. Liver Cancer. 2022 Feb 10;11(4):354-367. doi: 10.1159/000522547. eCollection 2022 Jul. PubMed 35978604 ↗
  • Kudo M, Ueshima K, Ikeda M, Torimura T, Tanabe N, Aikata H, Izumi N, Yamasaki T, Nojiri S, Hino K, Tsumura H, Kuzuya T, Isoda N, Yasui K, Aino H, Ido A, Kawabe N, Nakao K, Wada Y, Yokosuka O, Yoshimura K, Okusaka T, Furuse J, Kokudo N, Okita K, Johnson PJ, Arai Y; TACTICS study group. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut. 2020 Aug;69(8):1492-1501. doi: 10.1136/gutjnl-2019-318934. Epub 2019 Dec 4. PubMed 31801872 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2010, a primary completion of Mar 2018 and a completion of Mar 2018. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2010
First posted
Oct 8, 2010
Start
Oct 2010
Primary completionEst.
Mar 2018
CompletionEst.
Mar 2018
Last update
Oct 31, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 31, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01217034
Lead sponsor
Kindai University
Responsible party
Masatoshi Kudo (Professor, Kindai University Faculty of Medicine, Department of Gastroenterology and Hepatology, Kindai University) — Principal investigator
First posted
Oct 8, 2010
Start date
Oct 2010
Primary completion
Mar 2018 (estimated)
Completion
Mar 2018 (estimated)
Last update
Oct 31, 2017

Study contacts

Masatoshi Kudo, Professor
principal investigator · Kindai University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sorafenib

Start the discussion